scholarly journals Review of Hepatitis B Vaccination in Children of Workers of an Oil & Gas Industry in Lho'seumawe and Lho'sukon, North Aceh

2018 ◽  
Vol 34 (7-8) ◽  
pp. 209-15
Author(s):  
Chairul Adillah Harahap ◽  
Sari Leyli Harahap ◽  
Chairuddin P. Lubis ◽  
Ahmad Judin
Keyword(s):  
Immune Response ◽  
Hepatitis B ◽  
Medical Records ◽  
Hepatitis B Vaccination ◽  
Age Group ◽  
Gas Industry ◽  
The Third ◽  
Hepatitis B Vaccines ◽  
Fourth Dose ◽  
Oil Gas

We describe a retrospective study on hepatitis-B immunization in the Indonesian workers' children of Mobil-Oil Indonesia Lho' Seumawe and Lho'sukon, North Aceh. Data were obtained from medical records and included all children in the 0-15 years age group who had been immunized against hepatitis B types and schedules of vaccines, pre-immunization seromarkers, and anti HBsAb after the third immunization were recorded. For hundred and twenty children had received three doses of,hepatitis B vaccines; 180 children had them at 0, 1 and 2 months and the rest at 0, 1 and 6 months. Type of vaccine used was hunian plasma derived vaccine with a dosage of 5 µg per shot All of them (except the newborns) were tested and had seromarkers negative to hepatitis 8 infection prior to immunization. Testing for immune response (HBsAb) 2-6 months after the third immunization could only be done in 213 children, where 168 (78.9%) showed HBsAb titer> 10 miU/ml, 5 (2,30Al) had HBsAb < 10 miU/ml, and the remaining 40 (18,8%) showed no seroconversion. Of those 40 children who did not seroconversed, 31 were given a fourth dose, and 14 children were retested for their HBsAb titre. Seven children had positive responses and the rest remained negative.

scholarly journals 12 Months Persistent Immunogenicity after Hepatitis B Vaccination in Patients with Type 2 Diabetes and Immunogenicity of Revaccination in Non-Responders: An Open-Label Randomized Controlled Trial

Vaccines ◽  
2021 ◽  
Vol 9 (12) ◽  
pp. 1407
Author(s):  
Bingfeng Han ◽  
Wu Liu ◽  
Juan Du ◽  
Hanyu Liu ◽  
Tianshuo Zhao ◽  
...  
Keyword(s):  
Immune Response ◽  
Hepatitis B ◽  
Controlled Trial ◽  
Geometric Mean ◽  
Response Rates ◽  
Gansu Province ◽  
Healthy People ◽  
Hepatitis B Vaccination ◽  
Diabetic Patients ◽  
Hepatitis B Vaccines

Background: In initial studies, the immunogenicity and safety of hepatitis B vaccines in patients with diabetes has been assessed in China. Methods: In six township health centers in Gansu Province, 232 diabetic patients and 77 healthy people were allocated to receive two 3-dose hepatitis B vaccines (Group D20SC 0-1-6; Group D20CHO 0-1-6; Group ND20SC 0-1-6). Participants were followed up at 12 months after being fully vaccinated. One dose of the vaccine was randomly administered to non-responders. Chi-square test was used to compare the differences in response rate between two groups. Results: The anti-HBs response rates of three groups decreased from 84.1%, 89.1% and 88.3% at one month to 64.6%, 79.8% and 71.4% at twelve months. There was no statistical difference in the immune response rates between Group D20SC 0-1-6 and Group ND20SC 0-1-6; however, that of Group D20CHO 0-1-6 was higher than that of Group D20SC 0-1-6. After revaccination, the geometric mean concentrations were 491.7 mIU/mL and 29.7 mIU/mL after using vaccines containing 60 μg and 20 μg HBsAg. Conclusions: At 12 months, immune response in diabetic patients were not significantly different from that in healthy people. Revaccination with one dose of hepatitis B vaccine containing 60 μg HBsAg for non-responders was more satisfactory.

scholarly journals Immune Response Among the Children to Hepatitis B Vaccination: A Community-based Study in Bangladesh

2018 ◽  
Vol 44 (2) ◽  
pp. 103-108
Author(s):  
Mohammad Monir Hossain ◽  
Ahmed Nawsher Alam ◽  
Mahmuda Siddiqua ◽  
Ayesha Siddika ◽  
Afzalun Nessa
Keyword(s):  
Immune Response ◽  
Hepatitis B ◽  
Booster Dose ◽  
Protective Efficacy ◽  
Hepatitis B Vaccination ◽  
Age Group ◽  
Breakthrough Infection ◽  
Protective Level ◽  
Hbv Vaccine ◽  
Public Health Burden

Hepatitis B virus infection is a vaccine preventable infection of liver which remains a key public health burden globally. The development of Anti-HBs titre greater than or equal to 10 IU/L is considered as protective immunity and any titre less than 10 IU/L as non-protective following HBV vaccination. There is no comprehensive and authentic data regarding the immune response even 10 years after the integration of the HBV vaccine in to the EPI programme in Bangladesh and specifically, in Brahmonbaria district. The study was also aimed to assess the long term immune response among HBV vaccinated children. Blood sample from 500 vaccinated children were tested for Anti-HBs, and anti-HBc. Sero negative children were given 1 dose of HBV vaccine as a booster. Samples from booster vaccine were taken one month later and tested for anti Hbs titre. Anti HBs titre was found below protective level in about 46.0% (230/500) participants. Sero-protection rate decreased to 72.2% in 5 to 6 years age group which further decreased to 58.3% in 7 to 9 years age group and increased again to 69.5% in 10 to 12 years age group children. On the other hand, the mean anti Hbs titre was 97.72 IU/L initially and then increased with the increasing of age from 165.40 IU/L to 196.67 IU/L. Breakthrough infection of HBV was seen in 1.2% (6/500) participants measuring by anti HBc which indicated protective efficacy of HBV vaccine was about 98.8% (494/500). Sero negative participants were given a booster dose; 93.6% (131/140) participants showed boosting of mean anti HBs titre upto 804.92 IU/L which was below protective level (<10 IU/L) before booster dose. Anti-HBs titre goes below with the increase of age after vaccination. Most of the participants had immunological memory which will boost antibody titre after any exposure, so routine booster dose is not needed. But non-responder to vaccination should screen after primary vaccination because of chance of breakthrough infection.

scholarly journals STUDY OF IMMUNE RESPONSE AFTER HEPATITIS B VACCINATION IN DOCTORS

2020 ◽  
Vol 4 (6) ◽  
Author(s):  
B.L. Meena ◽  
Nikhil Gandhi ◽  
M.P. Sharma
Keyword(s):  
Immune Response ◽  
Hepatitis B ◽  
Booster Dose ◽  
Booster Vaccination ◽  
Primary Vaccination ◽  
Vaccination Status ◽  
Hepatitis B Vaccine ◽  
Hepatitis B Vaccination ◽  
Age Group ◽  
Seroprotection Rate

Background: Aim of our study was to evaluate the immune response after hepatitis B vaccination and to determine the duration of protective levels of HBsAb titre in doctors. From our study we concluded that hepatitis-B vaccine gives protection for more than 10 years after primary vaccination and booster dose of Hepatitis-B vaccine is not required in immunocompetent persons after primary vaccination. Method: In this study total 100 doctors of our institution were included who were vaccinated against hepatitis B. Data were obtained regarding age, sex, weight, height, BMI and duration of vaccination period. Doctors with no prior vaccination or incomplete vaccination or those who took booster vaccination were excluded from this study. Results: The mean titre was observed to be higher in 30 to 34 years of age group (584.42±4.03.21) as compared to age group of less than 25 and greater than 40 years. Moreover, males were observed to have higher mean titre as compared to females. (411.64± 417.27 vs 333.66± 431.49) but not statistically significant.  Similar with age and sex, duration of vaccination status was also not statistically significant. When we compared the  duration of vaccination status with  age group , mean titre was more in ≥30 years of age group as compared to <30 years (younger age groups) but statistically significant relation was observed only with the 1 month to <5 years of duration. Conclusion: From our study we concluded that hepatitis-B vaccinegives protection for more than 10 years after primary vaccination and booster dose of Hepatitis-B vaccine is not required inimmuno-competent persons after primary vaccination. Keywords: HbsAg titre , HepatitsB vaccine , seroprotection rate.

A Hepatitis B Vaccination Program in a Community Teaching Hospital

1987 ◽  
Vol 8 (3) ◽  
pp. 102-107 ◽  
Author(s):  
Myron J. Tong ◽  
Ann M. Howard ◽  
Gary C. Schatz ◽  
Mark A. Kane ◽  
Deborah A. Roskamp ◽  
...  
Keyword(s):  
Hepatitis B Virus ◽  
Hepatitis B ◽  
Previous History ◽  
Hepatitis B Vaccine ◽  
Hepatitis B Vaccination ◽  
Anamnestic Response ◽  
Low Level ◽  
B Virus ◽  
Fourth Dose ◽  
Hb Vaccine

AbstractPrior to offering the hepatitis B (HB) vaccine, a prescreen for hepatitis B virus (HBV) antibodies was conducted in a 565 bed hospital in Pasadena, California. Antibodies to the hepatitis B virus were detected in 14.5% of 1,745 employees tested. There was a significantly higher prevalence in those with a previous history of hepatitis, blood transfusions, exposure to nee-dlesticks, number of years in the same occupation, and in the same hospital work area. Employees of Asian extraction (33.3%) and blacks (23.1%) had a higher prevalence of antibodies to the hepatitis B virus than Hispanics (13.7%) and whites (10.2%). Anti-HBs was detected in 92.6% of 865 employees who received three doses of the hepatitis B vaccine. Only 28.6% of nonresponders receiving a fourth dose of hepatitis B vaccine produced anti-HBs. The nonresponders to the HB vaccine were older (average age 64.9 years) when compared to the responders (average age 37.5 years), and more males failed to produce anti-HBs after vaccination than females. Hepatitis B vaccination of the majority of individuals with either “low level” anti-HBs alone or anti-HBc alone did not elicit an anamnestic response after one dose of vaccine, implying that these “low level” antibodies are nonspecific and do not represent antiviral antibodies. Adverse reactions to the hepatitis B vaccine were minor and included a flulike syndrome, sore arm, and rash and swelling at the injection site. The reasons for nonparticipation were obtained from 179 individuals, and the main issue was concern about safety of the hepatitis B vaccine.

Effect of Oral Levamisole Supplementation to Hepatitis B Vaccination on the Rate of Immune Response in Chronic Hemodialysis Patients

Nephron ◽  
2000 ◽  
Vol 84 (3) ◽  
pp. 291-292 ◽  
Author(s):  
M. Deniz Ayli ◽  
Cüneyt Ensari ◽  
Meltem Ayli ◽  
Fahri Mandiroglu ◽  
Suat Mut
Keyword(s):  
Immune Response ◽  
Hepatitis B ◽  
Hemodialysis Patients ◽  
Chronic Hemodialysis ◽  
Hepatitis B Vaccination

scholarly journals Hepatitis B vaccination status and vaccine immune response among children in rural Senegal

2019 ◽  
Vol 29 (Supplement_4) ◽  
Author(s):  
L Perieres ◽  
M Coste ◽  
S Ndiour ◽  
P Halfon ◽  
C Sokhna ◽  
...  
Keyword(s):  
Immune Response ◽  
Hepatitis B ◽  
Chronic Infection ◽  
Vaccination Status ◽  
Hbv Infection ◽  
Hepatitis B Vaccination ◽  
Chronic Hbv Infection ◽  
Hbv Vaccination ◽  
Chronic Hbv ◽  
Vaccine Immunity

Abstract Background Hepatitis B vaccination during childhood is key to reduce the prevalence of Hepatitis B virus (HBV) infection. In Senegal, a highly endemic country, the three-dose hepatitis B vaccine and the birth dose vaccine were introduced in the Expanded Programme on Immunization (EPI) in 2004 and 2016 respectively. This study aimed to determine chronic HBV infection prevalence, hepatitis B vaccination status and vaccine immunity among children in Senegal. Methods A cross-sectional study including HBV screening was conducted at home among children aged 6 months to 15 years (i.e. born after the introduction of the HBV vaccine in the EPI) in the rural zone of Niakhar. Dried Blood Spot (DBS) samples were collected for the detection of HBsAg, anti-HBc Ab and anti-HBs Ab using chemoluminescence. Vaccination status was assessed using information on vaccination cards. Detectable vaccine immunity was defined with an adjusted DBS threshold of DOI≥0.36 IU/mL (corresponding to 10 IU/mL in venous blood sampling). Results Between October and December 2018, 455 children were enrolled. Preliminary results show that 7/455 (1.5%) had been in contact with HBV (positive anti-HBc Ab) and 5/455 (1.1%) had chronic HBV infection (positive HBsAg). Only 161/455 (35.4%) children had a vaccination card available. Among those, 150/161 (93.2%) received at least 3 doses of hepatitis B vaccine, of which 83/150 (55.3%) had detectable vaccine immunity. The proportion of children with detectable vaccine immunity was significantly higher in children &lt;5 years than in children aged 5-9 and 10-15 (72.3% versus 47.3%, p = 0.006 and 72.3% versus 14.3%, p &lt; 0.001). Conclusions Preliminary results suggest a low prevalence of HBV chronic infection among children born after the introduction of HBV vaccination in Senegal. However, detectable vaccine immunity rapidly decreases with age among vaccinated children, signalling a need for further studies on the immune response to HBV vaccination in this context. Key messages HBV chronic infection is low among children born after the introduction of HBV vaccination in Senegal. Further studies on the immune response to HBV vaccination in this context are needed.

Management of Health Care Workers Remotely Vaccinated for Hepatitis B Who Sustain Significant Blood and Body Fluid Exposures

1988 ◽  
Vol 9 (10) ◽  
pp. 462-464 ◽  
Author(s):  
Michael B. Snyder
Keyword(s):  
Health Care ◽  
Hepatitis B ◽  
Mucous Membrane ◽  
Health Care Workers ◽  
Body Fluid ◽  
Hepatitis B Vaccination ◽  
Recombinant Hepatitis ◽  
Care Workers ◽  
Hepatitis B Vaccines ◽  
Duration Of Protection

The availability of both plasma-derived and recombinant hepatitis B vaccines has given hospitals and other health care institutions the possibility of significantly reducing a major infectious hazard in the workplace. With the increasing use and acceptance of these vaccines, many employees who have a significant blood or body fluid exposure (percutaneous or mucous membrane) have already completed hepatitis B vaccination. Concerns have arisen over the duration of protection of vaccination, as it has been over five years since the introduction of the plasma-derived vaccine.

Sign in / Sign up

Export Citation Format

Share Document